FDA Warns of Severe Allergic Reactions With Certain Multiple Sclerosis Drugs
Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial
Executive Orders Suggest Swift Pivot in Managed Care and Health Policy
Dermocosmetics as Adjunctive Therapy Reduces Sensitivity and Improves Quality of Life in Acne